Trials / Completed
CompletedNCT02539927
Validation Study of the SAGIT® Instrument in Acromegaly
International Multicentre Validation Study of SAGIT® Instrument in Acromegaly
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 227 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients will be treated in accordance with the standard medical practice of the hospital where they have been recruited during their participation in this study. No additional assessments or tests will be required. SAGIT® is a new instrument developed by a group of acromegaly experts to help practicing endocrinologists to manage acromegalic patients and disease activity in their clinical practice and define acromegaly staging. It reports 5 elements: Signs and symptoms - S; Associated comorbidities - A; Growth hormone (GH) concentration - G; Insulin-like growth factor 1(IGF-1) concentration -I; Tumour size- T. The instrument has been pre evaluated during a qualitative pilot study. The purpose of the validation study is to define and validate the scoring of the SAGIT® instrument.
Conditions
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2018-09-03
- Completion
- 2018-09-03
- First posted
- 2015-09-03
- Last updated
- 2018-11-01
Locations
33 sites across 10 countries: United States, Belgium, Brazil, Denmark, France, Germany, Italy, Netherlands, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02539927. Inclusion in this directory is not an endorsement.